Invitrogen beats Street EPS

Research tool supplier IVGN reported third quarter EPS of $0.57, beating the Street consensus estimate

Read the full 153 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE